Carcinotech
- Company typePrivate
- Founded2018
- HeadquartersEdinburgh, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Carcinotech firmographics
Firmographics- Name
- Carcinotech
- Legal name
- Carcinotech Ltd.
- Website
- https://carcinotech.co.uk
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Carcinotech industry classification
Industry- Product category
- Preclinical Oncology Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Carcinogenicity Studies (HLAGAFAG)
Keywords
Where Carcinotech is headquartered
LocationHeadquarters
- HQ city
- Edinburgh
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Carcinotech business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Revenue model
- Preclinical Oncology Services: Provides end-to-end preclinical oncology services including biopsy sourcing, 3D tumor printing, and assay development. Services are delivered directly to biotech and pharmaceutical clients for cancer research and drug development applications.
- Custom Assay Development: Bridges resource gaps for clients by designing and executing custom assays on their behalf, delivering scientific insights for drug testing and optimization.
- Patient-Derived Tumor Models: Provides assay-ready, patient-derived 3D-printed tumor models for drug testing, optimization, and precision medicine applications.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
Carcinotech product offering
Product offeringCore offering
Carcinotech manufactures 3D-bioprinted, patient-derived living tumor models from biopsies for use in preclinical oncology research. The company offers end-to-end services covering biopsy sourcing, 3D tumor development that retains native microenvironments, and custom oncology assay execution for biotech and pharmaceutical clients. These models are used for early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities.
Product overview
Carcinotech offers a unified preclinical oncology services platform centered on its Carcino3D™ 3D bioprinting technology. The platform comprises biopsy sourcing services, 3D tumor development, and oncology assay services. These services support early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities including immunotherapies, monoclonal antibodies, hormone therapies, cancer vaccines, targeted therapies, oncolytic virus therapies, radioimmunotherapies, chemotherapies, and gene therapies. The company also provides specific tumor model products including lung, ovarian, and GBM models.
Differentiator
Problem solved
Functional benefit
Products and services
- Carcino3D™ Platform Carcinotech's core proprietary 3D bioprinting technology platform that creates patient-derived micro-tumors from biopsies for drug screening and personalized cancer treatment testing. Enables precise simulation of tumor microenvironments for biotech and pharmaceutical clients.
- Biopsy Sourcing Service
Quantifiable outcome
- 50+ diverse tumor biopsies available for research studies
- +2 more outcomes
Companies that use Carcinotech
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles1 record
Carcinotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Carcinotech partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Global Partners (unspecified)coreCompany collaborates with global partners to improve predictive models for cancer therapies and advance oncology drug development.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Carcinotech competitors and assessment
Company assessmentEmerging players
- Cypre: Cypre is an early-stage company developing 3D tumor models and screening platforms for cancer drug discovery. It competes in the same niche of 3D-printed or 3D-cultured tumor models for preclinical oncology.
- Regemat3D: Regemat3D develops 3D bioprinting technology for tissue and disease modeling applications including oncology research. It shares technology overlap with Carcinotech in the 3D bioprinting space.
- Lena Biosciences: Lena Biosciences focuses on 3D bioprinting and tissue engineering for drug screening applications. It shares 3D bioprinting technology overlap with Carcinotech's Carcino3D™ platform.
- SynVivo: SynVivo provides microfluidic organ-on-chip platforms for preclinical drug testing and disease modeling. It overlaps with Carcinotech in offering human-relevant preclinical models for drug development.
Direct peers
- Crown Bioscience: Crown Bioscience is a leading preclinical CRO specializing in oncology with extensive patient-derived xenograft (PDX) and organoid services. It directly competes with Carcinotech in providing preclinical oncology models for drug development to pharma and biotech clients.
- InSphero: InSphero specializes in 3D cell culture technology and organoid models for drug discovery and toxicology applications. It competes with Carcinotech in offering physiologically relevant 3D in vitro models for pharmaceutical preclinical research.
- MIMETAS: MIMETAS develops organ-on-chip and 3D tissue models for preclinical drug testing across multiple therapeutic areas including oncology. It overlaps with Carcinotech in providing 3D biology solutions for pharma drug development.
- CN Bio: CN Bio provides organ-on-chip and microphysiological systems for drug discovery, including oncology applications. It represents a comparable emerging player in the 3D biology preclinical services market.
Broad incumbents
- Charles River Laboratories: Charles River Laboratories is a large incumbent CRO offering comprehensive preclinical oncology services alongside broader drug development capabilities. It represents the scaled incumbent competing for the same pharma preclinical budgets as Carcinotech.
- Molecular Devices: Molecular Devices provides 3D biology instrumentation, imaging, and assay solutions for drug discovery. It operates as an enabling platform provider to the 3D biology market in which Carcinotech operates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
Carcinotech social profiles
Digital presenceCarcinotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Carcinotech leadership team
Management profileNumber of profiles
Profiles1 record
Carcinotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Carcinotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Carcinotech
What does Carcinotech do?
Carcinotech manufactures 3D-bioprinted, patient-derived living tumor models from biopsies for use in preclinical oncology research. The company offers end-to-end services covering biopsy sourcing, 3D tumor development that retains native microenvironments, and custom oncology assay execution for biotech and pharmaceutical clients. These models are used for early drug discovery, preclinical testing, and personalized medicine applications across multiple cancer therapy modalities.
Is Carcinotech a public or private company?
Carcinotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Carcinotech founded?
Carcinotech was founded in 2018. It employs 11 to 50 people.
Where is Carcinotech based?
Carcinotech is headquartered in Edinburgh, United Kingdom, in the Europe region.
How does Carcinotech make money?
Three revenue lines are on record. Preclinical Oncology Services are the primary driver. The others are custom Assay Development and patient-Derived Tumor Models.
Who are Carcinotech's main competitors?
Emerging players on record are Cypre, Regemat3D, Lena Biosciences and SynVivo. Direct peers are Crown Bioscience, InSphero, MIMETAS and CN Bio. Broad incumbents are Charles River Laboratories and Molecular Devices.
Does Carcinotech have an API?
No public API is recorded for Carcinotech.
What industry is Carcinotech in?
Carcinotech's product category is Preclinical Oncology Services. Its primary akta.pro industry code is HLAGAFAG, Carcinogenicity Studies. Its NAICS code is 541714 and its SIC code is 8731.